Patients with Huntington’s disease, a fatal genetic illness that causes the breakdown of nerve cells in the brain, have up to 80 percent less cancer than the general population.
Northwestern Medicine scientists have discovered why Huntington’s is so toxic to cancer cells and harnessed it for a novel approach to treat cancer, a new study reports.
Huntington’s is caused by an over abundance of a certain type of repeating RNA sequences in one gene, huntingtin, present in every cell. The defect that causes the disease also is highly toxic to tumor cells. These repeating sequences — in the form of so-called small interfering RNAs — attack genes in the cell that are critical for survival. Nerve cells in the brain are vulnerable to this form of cell death, however, cancer cells appear to be much more susceptible.
“This molecule is a super assassin against all tumor cells,” said senior author Marcus Peter, the Tom D. Spies Professor of Cancer Metabolism at Northwestern University Feinberg School of Medicine. “We’ve never seen anything this powerful.”
Huntington’s disease deteriorates a person’s physical and mental abilities during their prime working years and has no cure.
The study will be published Feb. 12 in the journal EMBO Reports.
To test the super assassin molecule in a treatment situation, Peter collaborated with Dr. Shad Thaxton, associate professor of urology at Feinberg, to deliver the molecule in nanoparticles to mice with human ovarian cancer. The treatment significantly reduced the tumor growth with no toxicity to the mice, Peter said. Importantly, the tumors did not develop resistance to this form of cancer treatment.
Peter and Thaxton are now refining the delivery method to increase its efficacy in reaching the tumor. The other challenge for the scientists is figuring out how to stabilize the nanoparticles, so they can be stored.
First and co-corresponding author Andrea Murmann, research assistant professor in medicine at Feinberg, also used the molecule to treat human and mouse ovarian, breast, prostate, liver, brain, lung, skin and colon cancer cell lines. The molecule killed all cancer cells in both species.
The Huntington’s cancer weapon was discovered by Murmann, who had worked with Peter on earlier research that identified an ancient kill-switch present in all cells that destroys cancer.
“I thought maybe there is a situation where this kill switch is overactive in certain people, and where it could cause loss of tissues,” Murmann said. “These patients would not only have a disease with an RNA component, but they also had to have less cancer.”
She started searching for diseases that have a lower rate of cancer and had a suspected contribution of RNA to disease pathology. Huntington’s was the most prominent.
When she looked at the repeating sequences in huntingtin, the gene that causes the disease, she saw a similar composition to the earlier kill switch Peter had found. Both were rich in the C and G nucleotides (molecules that form the building blocks of DNA and RNA).
“Toxicity goes together with C and G richness,” Murmann said. “Those similarities triggered our curiosity.”
In the case of people who have Huntington’s, the gene huntingtin has too many repeating sequences of the triplet sequence CAG. The longer the repeating sequence, the earlier they will develop the disease.
“We believe a short-term treatment cancer therapy for a few weeks might be possible, where we could treat a patient to kill the cancer cells without causing the neurological issues that Huntington’s patients suffer from,” Peter said.
Peter also is co-leader of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Huntington’s patients have a lifetime exposure to these toxic RNA sequences, but generally don’t develop symptoms of the disease until age 40, he noted.
Every child of a parent with Huntington’s has 50/50 chance of carrying the faulty gene. Today, there are approximately 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.
Learn more: Huntington’s disease provides new cancer weapon
The Latest on: Cancer therapy
- Lemonade stand raises $22,000 for pediatric cancer treatment on September 19, 2018 at 7:07 pm
BELLEAIR BLUFFS, Fla. -- A lemonade stand raised more than $22,000 for the National Pediatric Cancer Foundation. That money will be used to help a child get treatment that is not covered by insurance. ... […]
- Lung Cancer PDT: Old Treatment, New Results on September 19, 2018 at 7:06 pm
Lung cancer is the second most common cancer in both men and women. Treating it has been a huge challenge. But now, a treatment that's been around for decades is being used in a new way, and the ... […]
- Pediatric cancer patients get break from treatment in Chicago on September 19, 2018 at 2:40 pm
Many of the kids who toured Chicago with Sunshine kids met for the first time Tuesday but they already have something in common - they are all cancer patients. The Sunshine Kids Foundation,a ... […]
- 4 little girls celebrate beating cancer by remaking the photo they took while in treatment on September 19, 2018 at 11:15 am
What a difference two years can make. For four little girls, two years brought them friendship, health, and hair, and all of that is evident in sweet before and after photos shared by the Johns Hopkin... […]
- Texas Siblings Surprise Dad With Ford Mustang Sold to Pay Cancer Treatment 17 Years Ago on September 19, 2018 at 9:08 am
According to My SA, the white Ford Mustang played a big role in the family as Jake and Jeni rode in it when they were toddlers. When their mother was diagnosed with ovarian cancer in the early 2000s, ... […]
- CTLA4 targeted therapy plus PD-1 targeted therapy could benefit women with ovarian cancer on September 19, 2018 at 8:49 am
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor ... […]
- PhoenixMD secures $2.7 mln to advance cancer treatment on September 19, 2018 at 7:32 am
Vancouver-based biotechnology company Phoenix Molecular Designs (Phoenix MD) has raised $2.7 million in financing. The round included $2 million of equity, led by Canadian venture capital firm Pallasi... […]
- Novartis $372,000 Cancer Drug Hits First Hurdle in Europe on September 19, 2018 at 1:59 am
Novartis AG’s cancer drug Kymriah faced its first setback in Europe as U.K. health authorities made an initial recommendation against paying for the breakthrough therapy to treat a form of lymphoma in ... […]
- Children surprise dad with Mustang he sold 17 years ago to pay for mom's cancer treatment on September 18, 2018 at 4:30 pm
Everyone has that one car in their life. For whatever reason, it’s the one that sticks out in your memory as being your car. For some, it’s the car they learned to drive in, or the first they got to f... […]
- Glenn Ellis: Gaining control over cancer treatment on September 18, 2018 at 11:39 am
The very thought of having chemotherapy frightens many people. But knowing what chemotherapy is, how it works, and what to expect can often help calm your fears. It can also give you a better sense of ... […]
via Google News and Bing News